Evidence map›Paper›PMID 17382109›Full record

ArticleThe Journal of pediatrics2007

Neonatal hydrocortisone treatment: neurodevelopmental outcome and MRI at school age in preterm-born children.

Karin J Rademaker, Cuno S P M Uiterwaal, Floris Groenendaal, Monica M A T Uniken Venema, Frank van Bel, Frederik J Beek, Ingrid C van Haastert, Diederick E Grobbee, Linda S de Vries

Registry-linked trialAbstract readControlled Clinical Trial
PubMed Publisher
In one paragraph

Article in The Journal of pediatrics, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07248761 (Efficacy of Early Administration of Hydrocortisone in Shock in Preterm Neonates of Less Than 1,500 g), which is not on this map. Cited by 32 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 2 pooled it
6.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07248761 phase4active not recruitingnot on this mapstarted 2025, after this paper: background citation

Efficacy of Early Administration of Hydrocortisone in Shock in Preterm Neonates of Less Than 1,500 g

TypeinterventionalSponsorCoordinación de Investigación en Salud, MexicoRan2025 to 2026Enrolled76ConditionsShock, Preterm Birth Complication, Preterm Intraventricular Hemorrhage, Asphyxia PerinatalArmsIntravascular Hydrocortisone (stress dosage): 1 mg/k/dose each 8 hours for 5 days, Vasoactive drug therapies
3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 97 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Neurodevelopmental Outcome at 20 Months Corrected Age in Extremely Preterm Infants After Exposure to Dexamethasone and Hydrocortisone in the NICU.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2025
    Article
  9. Observational
  10. Does the Degree of Prematurity Relate to theJournal of Intelligence · 2023
    Article
  11. Article
  12. Screening for drugs potentially interfering with MCT8-mediated TJournal of endocrinological investigation · 2022
    Article
  13. Article
  14. Article
  15. Hydrocortisone and bronchopulmonary dysplasia: variables associated with response in premature infants.Journal of perinatology : official journal of the California Perinatal Association · 2020
    Article
  16. Bronchopulmonary dysplasia: Pathogenesis and treatment.Experimental and therapeutic medicine · 2018
    Review
  17. Review
  18. Article
  19. Neurodevelopmental impact of hydrocortisone exposure in extremely low birth weight infants: outcomes at 1 and 2 years.Journal of perinatology : official journal of the California Perinatal Association · 2015
    Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Karin J RademakerDepartment of Neonatology, University Medical Center Utrecht/Wilhelmina Children's Hospital, Utrecht, The Netherlands.
Cuno S P M Uiterwaal
Floris Groenendaal
Monica M A T Uniken Venema
Frank van Bel
Frederik J Beek
Ingrid C van Haastert
Diederick E Grobbee
Linda S de Vries
University Medical Center Utrecht · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate neurodevelopment at school age in preterm infants treated with hydrocortisone for bronchopulmonary dysplasia (BPD) in the neonatal period. STUDY

designPreterm infants (n = 226; gestational age < or = 32 weeks and/or body weight < or = 1500 grams) performed subtests of the Wechsler Intelligence Scale for Children-Revised, the Visual Motor Integration test, a 15-Word Memory Test and the Movement Assessment Battery for Children at school age. Conventional MRI of the brain was obtained. Sixty-two children who received hydrocortisone for BPD (starting dose, 5 mg/kg/day; median duration, 27.5 days) were compared with 164 nontreated neonates.

resultsHydrocortisone-treated infants were younger, lighter, and sicker than their non-steroid-treated counterparts. Adjustments for gestational age, body weight, sex, mechanical ventilation, and small for gestational age were made. Adjusted mean Intelligence Quotient, Visual Motor Integration test, and memory test results were the same in the hydrocortisone-treated group and the non-steroid-treated group (99 versus 101, P = .62; 97 versus 99, P = .49, 7.9 versus 7.5, P = .42, respectively). Motor function and incidence of cerebral palsy in both groups was not different (11% versus 7%, P = .97). Occurrence of brain lesions on MRI was similar for the two groups.

conclusionsNeonatal hydrocortisone treatment for BPD had no long-term effects on neurodevelopment.

Indexed as

Anti-Inflammatory AgentsBrain DiseasesBronchopulmonary DysplasiaChildChild DevelopmentCognitionFemaleHumansHydrocortisoneInfant, NewbornInfant, PrematureMagnetic Resonance ImagingMaleMotor SkillsNervous SystemTimeAnti-Inflammatory AgentsHydrocortisone

Identifiers

PMID17382109
OpenAlexW1979993325

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.